Karyopharm Therapeutics (KPTI) Other financing activities (2013 - 2025)
Karyopharm Therapeutics' (KPTI) quarterly Other financing activities came in at $405000.0 in Q4 2025, down 40.44% YoY from $680000.0 in Q4 2024, and down 40.44% on a QoQ basis from $680000.0 in Q4 2024.
Karyopharm Therapeutics (KPTI) Other financing activities (2013 - 2025) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 13 years of Other financing activities data on file, last reported at $405000.0 in Q4 2025.
- Quarterly Other financing activities fell 40.44% year-over-year to $405000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 million (up 14.94% YoY) and the FY2025 annual result came in at $761000.0, down 47.59% from the prior year.
- Other financing activities slipped to $405000.0 in Q4 2025, from $680000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $2.1 million in Q2 2021 to a low of $11000.0 in Q3 2022.
- A 5-year average of $827583.3 and a median of $816500.0 in 2021 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2021 — Other financing activities sank 98.71% — and 2024, when it jumped 157.58%.
- Tracing KPTI's Other financing activities over 5 years: stood at $896000.0 in 2021, then gained by 29.91% to $1.2 million in 2022, then sank by 77.32% to $264000.0 in 2023, then jumped by 157.58% to $680000.0 in 2024, then tumbled by 40.44% to $405000.0 in 2025.
- The last three Other financing activities figures came in at $405000.0 (Q4 2025), $680000.0 (Q4 2024), and $264000.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 405,000.00 |
| Dec 31, 2025 | 405,000.00 |
| Dec 31, 2024 | 680,000.00 |
| Dec 31, 2024 | 680,000.00 |
| Dec 31, 2023 | 264,000.00 |
| Dec 31, 2023 | 264,000.00 |
| Jun 30, 2023 | 860,000.00 |
| Jun 30, 2023 | 860,000.00 |
| Dec 31, 2022 | 1.16 Mn |
| Dec 31, 2022 | 1.16 Mn |
| Sep 30, 2022 | 11,000.00 |
| Sep 30, 2022 | 11,000.00 |
| Jun 30, 2022 | 1.34 Mn |
| Jun 30, 2022 | 1.34 Mn |
| Mar 31, 2022 | 1.47 Mn |
| Mar 31, 2022 | 1.47 Mn |
| Dec 31, 2021 | 896,000.00 |
| Dec 31, 2021 | 896,000.00 |
| Sep 30, 2021 | 16,000.00 |
| Sep 30, 2021 | 16,000.00 |